v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash Flows From Operating Activities:    
Net loss $ (7,907,712) $ (519,723)
Adjustments to reconcile net loss to net cash used in operating activities:    
Loss from written off property and equipment 24,492 11
Depreciation and amortization 167,293 241,218
Provision for credit losses 1,752,050 401,833
Share-based compensation 450,780
Changes in operating assets and liabilities:    
Accounts receivable 824,139 (1,943,829)
Accounts receivable - related party (332,832)
Inventories 42,434 150,967
Deferred contract costs (224,617) 315,747
Due from related parties (9,462) 26,052
Prepayments and other current assets (6,610,317) 232,979
Long term deposits (12,209) 10,633
Accounts payable 819,891 (733,088)
Deferred revenue 39,239 (298,462)
Due to related parties 12,571 (19,906)
Accrued expenses and other liabilities 1,812,727 315,580
Net cash used in operating activities (9,151,533) (1,819,988)
Cash flows from investing activities    
Acquisition of property and equipment (64,573) (144,366)
Capital injection from minority shareholder (18,413)
Net cash used in investing activities (64,573) (162,779)
Cash Flows From Financing Activities:    
Proceeds from bank loans 2,534,529 4,710,170
Repayment of bank loans (2,885,139) (3,152,082)
Sales of public shares through public offering 12,188,137
Net cash provided by financing activities 11,837,527 1,558,088
Effect of exchange rate changes on cash and restricted cash 662,243 (3,792)
Net increase (decrease) in cash and restricted cash 3,283,664 (428,471)
Cash and restricted cash at beginning of the year 798,958 1,227,429
Cash and restricted cash at end of the year 4,082,622 798,958
Supplemental Cash Flow Information    
Cash paid for interest expense 153,378 197,954
The following table identifies the balance sheet line items included in cash and restricted cash presented in the consolidated statements of cash flows:    
Cash 4,082,622 673,397
Restricted cash 125,561
Total 4,082,622 798,958
Share issuance under equity line of credit included in deferred offering cost $ 1,320,000